Sign in
CLLS Stock Price, Chart, Stats & News
Cellectis S.A.
Save
310.29M
Market cap
–
Current P/E
–
Forward P/E
CLLS chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 83.42% |
Operating margin | -55.32% |
Pretax margin | -102.35% |
Net margin | -92.34% |
Effective tax rate | 2.98% |
ROA | -20.81% |
ROE | -69.36% |
D/E | 1.58x |
Interest coverage ratio | -4.98x |
CLLS valuation
P/E | – |
P/S | 4.22x |
P/B | 4.07x |
P/CF | -7.82x |
P/FCF | -7.37x |
P/OCF | -7.82x |
PEG | 0.05x |
EV multiple | -12.40x |
About
Cellectis S. A. is a biotechnology firm in the clinical development stage, concentrating on the creation of immuno-oncology therapies. These therapies harness gene-edited T-cells engineered to express chimeric antigen receptors, designed to specifically identify and eliminate malignant cells.
Similar securities
Based on sector and market capitalization
Report issue